Can Changing the Prodrug Moiety in Remdesivir Be a Life-saving Strategy in COVID-19 Infection?

Overview

Journal Indian J Med Res

Specialty General Medicine

Date 2023 Apr 11

PMID 37040235

Authors

Praisy K Prabha

Ajay Prakash

Bikash Medhi

Affiliations

Soon will be listed here.

References

Tao S, Zandi K, Bassit L, Ong Y, Verma K, Liu P . Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. Curr Res Pharmacol Drug Discov. 2021; 2:100045. PMC: 8357487. DOI: 10.1016/j.crphar.2021.100045. View

Hartline C, Gustin K, Wan W, Ciesla S, Beadle J, Hostetler K . Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis. 2005; 191(3):396-9. DOI: 10.1086/426831. View

Lo M, Shrivastava-Ranjan P, Chatterjee P, Flint M, Beadle J, Valiaeva N . Broad-Spectrum Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524). Microbiol Spectr. 2021; 9(3):e0153721. PMC: 8612139. DOI: 10.1128/Spectrum.01537-21. View

Mackman R, Hui H, Perron M, Murakami E, Palmiotti C, Lee G . Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine -Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. J Med Chem. 2021; 64(8):5001-5017. DOI: 10.1021/acs.jmedchem.1c00071. View

Schooley R, Carlin A, Beadle J, Valiaeva N, Zhang X, Clark A . Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. Antimicrob Agents Chemother. 2021; 65(10):e0115521. PMC: 8448143. DOI: 10.1128/AAC.01155-21. View

Siegel D, Hui H, Doerffler E, Clarke M, Chun K, Zhang L . Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017; 60(5):1648-1661. DOI: 10.1021/acs.jmedchem.6b01594. View

Markovic M, Ben-Shabat S, Keinan S, Aponick A, Zimmermann E, Dahan A . Prospects and Challenges of Phospholipid-Based Prodrugs. Pharmaceutics. 2018; 10(4). PMC: 6321354. DOI: 10.3390/pharmaceutics10040210. View

Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V . Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021; 8:CD014962. PMC: 8406992. DOI: 10.1002/14651858.CD014962. View

Hostetler K, Beadle J, Trahan J, Aldern K, Owens G, Schriewer J . Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice. Antiviral Res. 2006; 73(3):212-8. PMC: 1859865. DOI: 10.1016/j.antiviral.2006.10.009. View

10.

Yan V, Muller F . Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. ACS Med Chem Lett. 2020; 11(7):1361-1366. PMC: 7315846. DOI: 10.1021/acsmedchemlett.0c00316. View

11.

Mackman R . Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. ACS Med Chem Lett. 2022; 13(3):338-347. PMC: 8887656. DOI: 10.1021/acsmedchemlett.1c00624. View

12.

Mahalmani V, Mahendru D, Semwal A, Kaur S, Kaur H, Sarma P . COVID-19 pandemic: A review based on current evidence. Indian J Pharmacol. 2020; 52(2):117-129. PMC: 7282680. DOI: 10.4103/ijp.IJP_310_20. View

13.

Ison M, Wolfe C, Boucher H . Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. JAMA. 2020; 323(23):2365-2366. DOI: 10.1001/jama.2020.8863. View

14.

Eastman R, Roth J, Brimacombe K, Simeonov A, Shen M, Patnaik S . Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci. 2020; 6(5):672-683. PMC: 7202249. DOI: 10.1021/acscentsci.0c00489. View

15.

Brown A, Won J, Graham R, Dinnon 3rd K, Sims A, Feng J . Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019; 169:104541. PMC: 6699884. DOI: 10.1016/j.antiviral.2019.104541. View

16.

Xiao D, Ling K, Tarnowski T, Humeniuk R, German P, Mathias A . Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies. Anal Biochem. 2021; 617:114118. PMC: 7835612. DOI: 10.1016/j.ab.2021.114118. View

17.

Chan-Tack K, Harrington P, Bensman T, Choi S, Donaldson E, ORear J . Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation. Antiviral Res. 2021; 195:105182. DOI: 10.1016/j.antiviral.2021.105182. View

18.

Pruijssers A, George A, Schafer A, Leist S, Gralinksi L, Dinnon 3rd K . Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020; 32(3):107940. PMC: 7340027. DOI: 10.1016/j.celrep.2020.107940. View

19.

Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A . Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19):1813-1826. PMC: 7262788. DOI: 10.1056/NEJMoa2007764. View